晚期结直肠癌分子靶向治疗

Targeted therapy of advanced colorectal cancer

晚期结直肠癌靶向治疗药物主要包括血管内皮生长因子抑制剂和表皮生长因子受体抑制剂。研究表明贝伐珠单抗和西妥昔单抗改善了晚期结直肠癌的预后，但在联合化疗药物方案的选择上稍有差异。西妥昔单抗和贝伐珠单抗改善K-ras野生型晚期结直肠癌患者总生存期相似。新的靶向药物阿柏西普、瑞格非尼等的出现，为晚期结直肠癌的靶向治疗提供了更多的选择。

Targeted agents for advanced colorectal cancer mainly include inhibitors of vascular endothe- lial growth factor （VEGF） and epidermal growth factor receptor （EGFR）. Studies show that bevacizumab and cetuximab can improve the prognosis of advanced colorectal cancer patients, but there is slight difference in the choice of chemotherapy regimens when combined with them. Bevacizumab and cetuximab can improve the over- all survival of K-ras wild-type colorectal cancer patients similarly. The emergence of new targeted drugs such as aflibercept, regorafenib provides more choices for the targeted therapy of advanced colorectal cancer patients.